About UPF0489 protein C5orf22
UPF0489 protein C5orf22 (C5orf22) is a protein
from Homo sapiens identified by UniProt accession
Q49AR2, 442 residues long.
MolForge cross-references it against 0 known binders and
12 disease associations.
Target properties
| Protein name | UPF0489 protein C5orf22 |
|---|
| UniProt accession | Q49AR2 |
|---|
| Gene | C5orf22 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 442 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (12)
Diseases linked to this target (Open Targets).
- body height · score 0.28
- neurodegenerative disease · score 0.26
- sleep apnea measurement · score 0.17
- sleep measurement · score 0.09
- non-alcoholic fatty liver disease · score 0.02
- blood protein measurement · score 0.02
- neoplasm · score 0.00
- Invasive Breast Carcinoma · score 0.00
- Gout · score 0.00
- astrocytoma · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q49AR2-F1 | alphafold | PREDICTED | 84.02 | — |
Amino-acid sequence (442 residues)
MSDSAGGRAG LRRYPKLPVW VVEDHQEVLP FIYRAIGSKH LPASNVSFLH FDSHPDLLIP VNMPADTVFD KETLFGELSI ENWIMPAVYA GHFSHVIWFH PTWAQQIREG RHHFLVGKDT STTTIRVTST DHYFLSDGLY VPEDQLENQK PLQLDVIMVK PYKLCNNQEE NDAVSSAKKP KLALEDSENT ASTNCDSSSE GLEKDTATQR SDQTCLEPSC SCSSENQECQ TAASTGEILE ILKKGKAFVL DIDLDFFSVK NPFKEMFTQE EYKILQELYQ FKKPGTNLTE EDLVDIVDTR IHQLEDLEAT FADLCDGDDE ETVQRWASNP GMESLVPLVQ SLKKRMEVPD YEMVHQAGLT CDYSELPHHI STEQEIECLI QSVHYLLKNL PNPTLVTIAR SSLDDYCPSD QVDTIQEKVL NMLRALYGNL DLQVYAAESP PS
Explore UPF0489 protein C5orf22 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets